1. United Kingdom Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
GSK plc

GSK plc

GLAXF
GSK plcUS flagOther OTC
25.50
USD
-1.13
- -
102.23BMarket Cap
GSK plc
GLAXF
(Other OTC)

Recent

price

25.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
6.97
6.81
6.73
6.86
5.98
6.19
7.17
7.72
7.84
8.53
6.12
6.17
7.28
7.48
7.7
8.06
8.12
Revenue per Share
0.4
1.31
1.14
1.41
0.72
2.18
0.23
0.39
0.92
1.17
1.44
1.1
3.71
1.22
0.63
1.41
1.44
Basic EPS, GAAP
1.27
1.22
0.73
1.43
0.89
0.17
1.07
1.21
1.69
1.48
1.63
1.32
1.28
1.09
0.88
1.17
1.18
Free Cash Flow per Basic Share
0.79
0.85
0.97
0.95
1
1
1.25
1
1
1
1
1
0.86
0.55
0.6
0.63
0.64
Dividend per Share
1.52
1.18
0.51
0.58
-0.19
-0.01
-1.04
-1.31
-0.35
1.48
2.04
2.32
1.42
2.12
2.24
2.85
3.21
Book Value per Share
-0.59
-0.68
-1.98
-1.47
-1.85
-3.35
-5.09
-5.07
-4.91
-5.85
-4.93
-4.82
-2.8
-2.17
-2.31
-1.93
-1.98
Tangible Book Value per Share
4,072
4,022
3,930
3,865
3,846
3,865
3,888
3,909
3,931
3,958
3,981
4,002
4,026
4,052
4,077
4,051
4,035
Basic Weighted Avg Shares
28,392
27,387
26,431
26,505
23,006
23,923
27,889
30,186
30,821
33,754
24,354
24,696
29,324
30,328
31,376
32,667
32,780
Sales/Revenue/Turnover
12.71
27.54
22.98
22.21
18.72
10.99
21.61
20.08
22.91
18.64
18.8
19.75
22.95
24.22
17.66
25.52
25.67
Operating Margin (%)
1,679
1,423
1,445
1,414
1,484
1,630
1,774
1,922
1,856
2,334
2,050
2,122
2,147
2,294
2,551
2,314
1,954
Depreciation Expense
1,634
5,261
4,499
5,436
2,756
8,422
912
1,532
3,623
4,645
5,749
4,385
14,956
4,928
2,575
5,716
5,829
Net Income, GAAP
41.31
29.1
29.12
15.33
4.62
20.46
45.23
38.47
15.71
15.32
1.3
2.31
12.56
12.47
15.13
15.02
14.54
Effective Tax Rate (%)
5.76
19.21
17.02
20.51
11.98
35.2
3.27
5.08
11.75
13.76
23.61
17.76
51
16.25
8.21
17.5
17.78
Profit Margin (%)
3,242
1,157
-123
1,550
1,383
3,170
-2,290
-10,662
-5,564
-4,559
-1,901
-4,996
-2,041
-2,424
-4,700
-3,881
-4,668
Working Capital
14,809
12,203
14,671
15,456
15,841
15,324
14,661
14,264
20,271
23,590
23,425
20,572
17,035
15,205
14,637
14,708
14,012
LT Debt
9,745
8,827
6,737
7,812
4,936
8,878
4,963
3,489
3,672
18,357
20,808
21,342
10,096
12,795
13,086
15,956
17,422
Total Equity
7.8
20.93
16.73
18.59
15.83
8.15
12.79
16.12
22.89
13.33
9.25
10.12
15.22
20.51
15.2
21.85
20.62
Return on Invested Capital (%)
8
26.29
23.31
27.6
16.74
46.37
5.93
7.91
18.88
14.04
14.02
10.88
45.53
19.84
10.63
21.05
19.93
Return on Capital (%)
23.45
96.06
133.34
256.42
- -
- -
- -
- -
- -
- -
82.26
50.43
199.4
68.94
29.05
55.22
51.6
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
2,856
3,012
5,044
LT Borrowings
- -
14,015
- -
LT Finance Leases
- -
693
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
4,026
4,013
4,020
Market Capitalization
63,263
74,167
83,189

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
17,842
17,510
17,761
Cash, Cash Equivalents & STI
3,306
3,159
3,443
Accounts Receivable, Net
7,937
5,913
7,756
Inventories
6,118
5,924
6,157
Total Current Liabilities
21,334
21,391
22,429
Payables & Accruals
- -
- -
- -
ST Debt
2,856
3,012
5,044
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
34.55%
0.16%
21.93%
Free Cash Flow
55.26%
-4.29%
33.15%
Net Income, GAAP
39.18%
44.9%
121.98%
Sales/Revenue/Turnover
3.97%
6.23%
4.11%
Total Cash Common Dividend
-2.67%
-6.85%
4.91%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
7,363
7,884
8,012
8,117
31,376
2025
7,516
7,986
8,547
8,618
32,667
2026
7,629
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.26
0.29
-0.01
0.1
0.63
2025
0.4
0.36
- -
0.16
1.41
2026
0.43
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.14
0.16
0.15
0.15
0.6
2025
0.15
0.16
- -
0.16
0.63
2026
0.16
- -
- -
- -
- -
Similar Companies
Grifols, S.A. (GIFLF)
Bristol-Myers Squibb Company Ce (CELG-RI)
GSK plc (GLAXF)
Pfizer Inc. (PFE.BA)
Aurora Optoelectronics Co.,Ltd. (600666.SS)
Organon & Co. (OGN)
Business
GSK plc is a global biopharmaceutical company specializing in the research, development, manufacture, and marketing of vaccines, specialty medicines, and consumer healthcare products. Its main product offerings include prescription pharmaceuticals in respiratory, immunology, inflammation, oncology, and HIV therapeutic areas; a broad portfolio of vaccines; and recently divested consumer healthcare products following separation from its prior consumer joint venture. GSK operates across more than 80 countries and markets its products in 122 countries, with headquarters in Brentford, United Kingdom. Founded in 1715 and rebranded as GSK plc in 2022, the company focuses primarily on biopharmaceuticals following its strategic demerger of the consumer healthcare segment. In recent major developments, GSK has accelerated its growth in specialty medicines through several strategic acquisitions and product launches. Noteworthy transactions include the acquisition of IDRx, a US-based biotechnology firm specializing in gastrointestinal stromal tumor treatments, finalized in early 2025 for approximately $1.15 billion, reinforcing its oncology portfolio. In 2024, GSK completed acquisition of Aiolos Bio, focusing on respiratory and inflammatory diseases, and Elsie Biotechnologies to enhance its oligonucleotide drug capabilities. The company announced five major new product approvals slated for 2025, including Blenrep for multiple myeloma and depemokimab for severe asthma, signaling strong pipeline progress with over 70 specialty medicines and vaccines in clinical development. Strategic alliances have also been formed, such as a research collaboration with Flagship Pioneering to advance therapies in respiratory, immunology, and inflammation. GSK’s business segments concentrate on specialty medicines including respiratory, immunology, oncology, and HIV, alongside vaccines, with sales growth driven notably by its specialty medicines portfolio. The company operates mainly in the U.S., Europe, and the UK markets. GSK has refined its corporate structure since its 2022 reorganization, prioritizing investment in innovation and R&D to maintain leadership in advanced biopharmaceutical treatments. Its long-term outlook expects sales exceeding £40 billion by 2031, supported by sustained research and development investments and a strong late-stage clinical pipeline. The company employs over 68,000 people globally and maintains a primary listing on the London Stock Exchange as part of the FTSE 100 Index. In leadership changes, GSK appointed Luke Miels as CEO starting in 2026, succeeding Emma Walmsley who led the company through a period of transformation and growth. Overall, GSK continues to evolve as a focused biopharma leader with an expanding portfolio in specialty medicines and vaccines, driven by strategic acquisitions, strong pipeline developments, and global market presence.

Company News

MCPAPIChat

  • proactiveinvestors.co.uk

    UBS says UK stocks are better supported but not broadly so, as earnings lead while sentiment drags

  • seekingalpha.com

    GSK plc (GSK) Q1 2026 Earnings Call Transcript